By: IPP Bureau
Last updated : October 25, 2025 10:09 am
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Syngene International Ltd., a leading global contract research, development, and manufacturing organization (CRDMO), announced plans to establish a state-of-the-art GMP bioconjugation suite at its commercial biologics facility (Unit 3) in Bengaluru.
The new facility will enable Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs)—from early discovery through to GMP manufacturing—positioning the company among a select group of CDMOs with comprehensive ADC development capabilities.
The OEB-5-rated suite will significantly accelerate ADC development timelines by allowing monoclonal antibody (mAb) production and GMP bioconjugation to occur at a single site. This expansion complements Syngene’s existing commercial capabilities in payload and linker manufacturing.
Expected to be operational within the current financial year, the facility will also support a range of advanced conjugates and related modalities.
The integration of analytical and bioanalytical capabilities within the same site will further streamline development processes, ensuring seamless data flow and enhanced quality control throughout the lifecycle.
“The discovery and development of ADCs is inherently complex, often involving multiple vendors and geographically dispersed sites, which introduces supply chain challenges and delays,” said Alex Del Priore, Head – LM CDMO, Syngene International.
“By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can compress development timelines and provide a true end-to-end solution—from early discovery through GMP manufacturing—for our global clients.”
The new laboratories will also provide process development, analytical characterization, and scale-up capabilities for early- and late-stage projects, strengthening Syngene’s position as a trusted partner for biotech and biopharma companies seeking agile, science-driven solutions.